Purpose: To identify resistance mechanisms for the chemotherapeutic drug fludarabine in chronic lymphocytic leukemia (CLL), as innate and acquired resistance to fludarabine-based chemotherapy represents a major challenge for long-term disease control.
Introduction
identified as enriched in patients relapsing after FCR or with FR disease (10) (11) (12) (13) (14) (15) (16) (17) . Regardless of this, there is still a significant fraction of CLL patients relapsing after FCR where the genetic cause of resistance remains elusive. Similar to other cancer types, NGS efforts in CLL require large patient cohorts and longitudinally collected samples to pinpoint new genetic alterations as causally involved in drug resistance and formal proof also requires experimental validation. Therefore, alternative approaches complementing the existing sequencing efforts in patients could greatly improve the interpretation of NGS data.
In this study, we performed a piggyBac transposon mutagenesis screen, which is the first forward genetic screen to identify genes modifying drug response in CLL. piggyBac transposon mutagenesis has been applied to identify mechanisms of chemotherapy resistance to purine analogues (6-thioguanine) and taxanes (paclitaxel), while also aiding the identification of novel second site mutations in BRAF in response to vemurafenib (18) (19) (20) .
Our analysis revealed both novel genes, not previously implicated in chemotherapy resistance in CLL, as well as genes already linked to refractory disease thus validating our approach. 
Materials and Methods

Cell culture
The human EBV-transformed, lymphoblastoid cell line HG3, established from a poorprognostic CLL patient with unmutated IGHV genes (further characterized in (21) Research. 
Cell viability assay
Following hygromycin selection of cells with transposon insertions, cell pools that were either treated or untreated with F-ara-A were tested for F-ara-A sensitivity using a resazurin viability assay. Briefly, 100,000 cells were seeded in 1 ml in triplicate wells in a 24-well plate and treated with increasing concentrations of F-ara-A (ranging from 1 to 64 μM) for 72h. To assess growth suppression, 44 μM resazurin (Sigma Aldrich) was added to the medium and fluorescence was measured in a Wallac Victor Multilabel Counter (Wallac, Turku, Finland) with excitation and emission wavelengths of 530 and 590 nm, respectively. The relative number of viable cells was expressed as percentage of untreated cells.
Splinkerette PCR
Genomic DNA was isolated from cell pools with the NucleoSpin DNA extraction kit (Machery Nagel). Splinkerette PCR was performed as described (22) . Briefly, following digestion of genomic DNA with Sau3AI, DNA was ligated to adaptors and a primary PCR reaction was performed with a Splink1-5'-CGAAGAGTAACCGTTGCTAGGAGAGACC-3' and HMsp1-5'-CGAAGAGTAACCGTTGCTAGGAGAGACC-3' primer pair (20) .
Secondary PCR was carried out with barcoded primers (Supplementary Material and Methods) and the products were treated with ExoSap. The barcoded samples were mixed in equimolar concentrations and sequenced on an Illumina HiSeq 2000 instrument.
Sequence processing and identification of genes with transposon integrations
To map the transposon integrations, the sequences were trimmed to remove the barcode and adaptor sequences, then aligned to human genome (hg19) using the Smalt software (www.sanger.ac.uk/resources/software/smalt, version 0.7.5.1, with default parameters). The mapped sequences were parsed to identify the genomic integration locations, together with the To assess the sensitivity to F-ara-A following transient or stable transfection cells were seeded in either 96-well plates (HCT116 and RKO; 8,000 cells/well) or 24-well plates (HG3; 100,000 cells/well) and treated with increasing concentrations of the drug (ranging from 2 to 128 μM for HCT116 and RKO cells and from 1 to 64 μM for HG3 cells) for 72h. The growth suppression was evaluated using a viability assay as described. 
Western blot
Real-time quantitative PCR
Total RNA was extracted using an RNeasy Plus Mini kit (Qiagen) and cDNA was synthesized 
RNA-sequencing
RNA samples were prepared as described. The RNA integrity and concentration was determined on a Bioanalyzer instrument (Agilent) using an RNA 6000 Nano kit. Samples were sequenced on the Ion Proton system (Ion Torrent/Life Technologies. In each sample, approx. 30~50 million reads were sequenced. The reads were aligned to the human genome hg19 assembly (https://genome.ucsc.edu) using Tophat2 software (version 2.0.4) (24) . The RNAseq read count quantification was performed using the HTSeq tool (version 0.6.1) (25).
To identify the gene expression differences between the three pairs of HG3 pools, DESeq2 software was used. (26) 
BRAF screening of CLL patient samples
Using whole-exome/genome sequencing, the mutation status of BRAF was assessed in 506 Spanish patients as recently reported (15) . In addition, samples from 247 untreated patients enrolled in the UK LRF CLL4 clinical trial (27) were investigated using targeted NGS including the BRAF gene.
Statistical analysis
Graphpad Prism 6.0b was used for statistical analysis. Dose-response data was analyzed using non-linear regression and log(inhibitor) vs response -variable slope (four parameters) to calculate IC 50 values from viability tests. Statistical significance was calculated using students T-test for IC 50 values for specific doses of F-ara-A. All data shown are based on at least three independent experiments. For the Spanish cohort, time-to-first-treatment (TTFT) was 
Valiation of genes mediating fludarabine resistance
Collectively, this screen identified 782 genes with transposon integrations not overlapping with genes identified in the non-selected pools (Supplementary Table S1 ). Among the top 10 most significantly targeted genes by the transposon insertions was deoxycytidine kinase (DCK), which encodes an essential step in the activation of the purine nucleoside analogue fludarabine, where it phosphorylates the nucleoside (F-ara-A) to nucleoside-monophosphate ( Figure S2 ) and protein (data not shown). Titration of F-Ara-A resulted in a 2.5-and 3.3-fold increase in IC 50 when BMP2K and DCK had been knocked-down as compared to HG3 cells expressing control shRNA (Figure 2A) .
To identify potentially clinically relevant mechanisms for acquired resistance to F-ara-A, the gene sets identified by piggyBac transposon mutagenesis were intersected with 148 genes found somatically mutated in CLL patients refractory to fludarabine-based therapy (12) .
Overall, 10 genes were found in common between the transposon and the genomic screen, which is a significant enrichment compared to the expected enrichment occurring by chance (hypergeometric probability P=0.034) ( Table 2) Figure   2B ). Given the low frequency of cells expressing the plasmids it is still a significant and sizable change. Over-expression of ARID5B resulted in a modest but significant increase in Fara-A IC 50 Figure 2C and data not shown).
The case of BRAF
A transposon insertion was identified in the first intron of the serine/threonine kinase BRAF, which is compatible with gene activation (Figure 2E) . Noteworthy, an activating L597Q BRAF mutation was recently identified in one patient reported to be refractory to fludarabinebased therapy (12) . To test if BRAF activation confers a reduced sensitivity to fludarabine, we used the colorectal RKO cell line that harbors the activating V600E mutation in BRAF and its isogenic derivative where the mutant alleles have been knocked-out. The presence of V600E was associated with significantly reduced sensitivity to higher doses of F-ara-A, as revealed by cell viability assay ( Figure 2D) . The difference in response to F-ara-A between BRAF mutant and wt cells was normalized by the addition of the BRAF V600E inhibitor vemurafinib, (Supplementary Figure S5) .
To investigate the significance of BRAF mutations in CLL patients, we analysed wholeexome/genome data available from a 'general practice' cohort. Ten of 506 patients carried non-synonymous BRAF mutations (median variant allele frequency, 36%, range, 17-58%).
Notably, patients with BRAF mutation had a significantly shorter TTFT compared to wildtype (median 0.5 vs 64.5 months, p<0.001), while no significant difference was seen for OS (median 128.0 vs 122.9 months, p=0.98), Figure 3 and Supplementary 
Discussion
Interpretation of data from large-scale cancer genome sequencing studies is often hampered by the high frequency of passenger mutations, sequencing artifacts and small cohort sizes.
Complementary approaches are therefore needed to assign relevant functions to genes identified as mutated in cancer in order to understand the genetics and biology driving cancer development and to provide insights into mechanisms of resistance to therapy. piggyBac transposon mutagenesis is a powerful forward genetics tool that can facilitate the identification of genes mediating resistance to chemotherapy. This technique has been successfully applied in transgenic mice as well as in cell culture systems for the discovery of genes driving cancer development and drug resistance (18-20, 30, 31) .
To determine genetic mediators of resistance to fludarabine, we performed a piggyBac transposon screen in the HG3 CLL cell line and identified 782 transposon-targeted genes in pools of cells exhibiting fludarabine resistance. The identification of DCK, a known determinant of cellular response to fludarabine, underscores that the screen has the power to detect biologically relevant genes. DCK encodes a rate-limiting kinase in the activation of the pro-drug F-ara-A to the nucleoside-monophosphate. Low levels of DCK have been shown to correlate with impaired response to fludarabine in CLL (32) . In addition, reduced levels of DCK were also observed in mantle cell lymphoma patients exhibiting refractoriness to cytarabine, a member of the same class of drugs as fludarabine (33) .
The piggyBac screen also identified BMP2K as a novel gene conferring resistance to fludarabine. BMP2K was first identified as a BMP2 inducible kinase that plays a role in osteoblast differentiation (34) and, together with BMP2, it was also shown to regulate eye development (35) . The role of BMP signaling in B-cell malignancies is less clear, but it was reported that BMP6 inhibits the growth of mature B cells and that epigenetic inactivation of (40, 41) . ARID5B is mutated in 6-23% of endometrial carcinoma, and Arid5b knockout mice exhibit defects in normal B cell development (39, 42) . In addition, the homologue ARID1A is a driver mutation in 1.6% of CLL patients and was also found mutated in splenic marginal zone lymphoma and germinal-center derived lymphomas (15, 43, 44) . Thus, ARID5B is a plausible novel candidate for affecting CLL progression and response to treatment.
Another gene that was common to both the piggyBac screen and the analysis of patients with FC-refractory CLL was BRAF, where our validation experiments using cancer cell lines with an activating V600E mutation in BRAF confirmed that its activation may lead to fludarabine resistance. BRAF mutations have been recurrently reported in CLL patients with a frequency of approximately 3% (12, 14, 15, 45, 46) . While the most prevalent BRAF mutation in cancer in general is V600E, which leads to a constitutive activation of BRAF, mutations other than V600E are more frequently seen in CLL without any obvious hot-spot (Supplementary Figure S8 and Table S6 ). However, most of them cluster within or near the activation loop where V600E resides and are known to confer variable, but increased signaling and oncogenic capacity (47) . Given that most of the mutations may lead to increased BRAF activity, we speculate that the BRAF mutations observed in the activation loop in CLL patients act in a similar way with regards to fludarabine sensitivity, even though we cannot rule out that mutations other than V600E might behave differently. Of note, activating mutations in other members of the MAPK pathway have also been reported in CLL, e.g. NRAS, KRAS, MAPK1 (ERK2) and ERG2 (14, 15, 45) . Hence, if one considers the entire MAPK pathway it is possible that its contribution to CLL pathobiology is larger than previously thought (45, 46) . It is upregulated in CLL and acts downstream of oncogenic KRAS and EGR1 (48, 49) .
PTPRE is a phosphatase expressed in leukocytes that is induced by antigen stimulation and regulates MAPK signaling (50) . VAV proteins are critical for T-and B-cell receptor-induced Ca 2+ signaling and NF-κB-mediated survival signaling in B cells (51, 52) . In line with our findings from the piggyBac screen, other studies have also suggested that RAF/MEK/ERK signaling has pro-survival effects under fludarabine treatment (53) (54) (55) .
CLL cells are dependent on stromal cell interaction in order to prevent apoptosis and this protective effect is partially due to CXCL12-CXCR4 interaction that leads to induction of all types of resistance patterns, and further investigation of additional CLL cell lines will be necessary to get different model systems representative of major CLL subtypes.
In conclusion, to our knowledge, this is the first forward genetic screen for genes mediating fludarabine resistance in an experimental system. Our data supports the notion that the combination of genetic screens in experimental systems and NGS-based mutational analyses of human samples complement each other in an efficient way to identify functionally relevant genes not only for CLL but also for other cancer types. In particular, we identified both known and novel mediators of fludarabine resistance, hence underscoring the broad applicability of this method and highlighting activation of BRAF/MAPK signaling and downstream targets as a central mechanism behind reduced fludarabine sensitivity in CLL.
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